Fennec Pharmaceuticals Inc.

NasdaqCM:FENC 株式レポート

時価総額:US$140.6m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Fennec Pharmaceuticals マネジメント

マネジメント 基準チェック /34

Fennec Pharmaceuticals'の CEO はRosty Raykovで、 Jul2009年に任命され、 の在任期間は 15.08年です。 の年間総報酬は$ 2.54Mで、 23.9%給与と76.1%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の0.34%を直接所有しており、その価値は$ 502.83K 。経営陣と取締役会の平均在任期間はそれぞれ8.8年と10.3年です。

主要情報

Rosty Raykov

最高経営責任者

US$2.5m

報酬総額

CEO給与比率23.9%
CEO在任期間15.2yrs
CEOの所有権0.2%
経営陣の平均在職期間8.8yrs
取締役会の平均在任期間10.4yrs

経営陣の近況

Recent updates

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be

Aug 15
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be

Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?

Jul 16
Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?

Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop

Jun 02
Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop

Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Apr 18
Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates

Nov 09
Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates

Fennec wins FDA approval of Pedmark for chemotherapy-induced ototoxicity in children

Sep 20

Buying Fennec Pharma Ahead Of September PDUFA For Pedmark

Aug 23

Fennec Pharmaceuticals secures up to $45M financing facility from Petrichor

Aug 01

Fennec Pharmaceuticals: Will Pedmark Make It To Market At Second Time Of Asking?

Oct 29

Fennec Could See Upside If Pedmark Gets Approved

Jul 29

Fennec Pharmaceuticals (FENC) Investor Presentation - Slideshow

Jun 18

Fennec Pharma resubmits PEDMARK application in U.S.

May 28

Fennec Pharmaceuticals (NASDAQ:FENC) Is In A Good Position To Deliver On Growth Plans

May 26
Fennec Pharmaceuticals (NASDAQ:FENC) Is In A Good Position To Deliver On Growth Plans

Breakeven On The Horizon For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Apr 01
Breakeven On The Horizon For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Do Institutions Own Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shares?

Mar 02
Do Institutions Own Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shares?

Have Insiders Been Selling Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shares This Year?

Jan 26
Have Insiders Been Selling Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shares This Year?

Companies Like Fennec Pharmaceuticals (NASDAQ:FENC) Are In A Position To Invest In Growth

Dec 22
Companies Like Fennec Pharmaceuticals (NASDAQ:FENC) Are In A Position To Invest In Growth

Fennec Pharmaceuticals EPS misses by $0.05

Nov 16

Fennec Pharmaceuticals: The Compensation Is What's Missing

Nov 05

CEO報酬分析

Fennec Pharmaceuticals の収益と比較して、Rosty Raykov の報酬はどのように変化したか?
日付総報酬給与会社業績
Jun 30 2024n/an/a

US$3m

Mar 31 2024n/an/a

US$3m

Dec 31 2023US$3mUS$607k

-US$16m

Sep 30 2023n/an/a

-US$20m

Jun 30 2023n/an/a

-US$26m

Mar 31 2023n/an/a

-US$26m

Dec 31 2022US$614kUS$503k

-US$24m

Sep 30 2022n/an/a

-US$21m

Jun 30 2022n/an/a

-US$17m

Mar 31 2022n/an/a

-US$16m

Dec 31 2021US$3mUS$468k

-US$17m

Sep 30 2021n/an/a

-US$16m

Jun 30 2021n/an/a

-US$18m

Mar 31 2021n/an/a

-US$19m

Dec 31 2020US$2mUS$430k

-US$18m

Sep 30 2020n/an/a

-US$18m

Jun 30 2020n/an/a

-US$14m

Mar 31 2020n/an/a

-US$14m

Dec 31 2019US$1mUS$489k

-US$13m

Sep 30 2019n/an/a

-US$12m

Jun 30 2019n/an/a

-US$13m

Mar 31 2019n/an/a

-US$11m

Dec 31 2018US$1mUS$350k

-US$10m

Sep 30 2018n/an/a

-US$9m

Jun 30 2018n/an/a

-US$9m

Mar 31 2018n/an/a

-US$8m

Dec 31 2017US$450kUS$263k

-US$7m

報酬と市場: Rostyの 総報酬 ($USD 2.54M ) は、 US市場 ($USD 1.54M ) の同規模の企業の平均を上回っています。

報酬と収益: Rostyの報酬は、過去 1 年間の会社の業績と一致しています。


CEO(最高経営責任者

Rosty Raykov (48 yo)

15.2yrs

在職期間

US$2,540,940

報酬

Mr. Rostislav Raykov, also known as Rosty, has been the Chief Executive Officer of c Pharmaceuticals Inc. since July 2009. Mr. Raykov is an Independent Director of Lavras Gold Corp. since April 1, 2022. Mr...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Rostislav Raykov
CEO & Director15.2yrsUS$2.54m0.24%
$ 341.5k
Robert Andrade
Chief Financial Officer8.8yrsUS$1.31m0.60%
$ 850.4k
Mark Gowland
Controller8.8yrsデータなしデータなし
Lei Fang
President of Pharstat Incno dataデータなしデータなし

8.8yrs

平均在職期間

経験豊富な経営陣: FENCの経営陣は経験豊富で経験豊富です(平均在職期間は8.8年)。


取締役

名称ポジション在職期間報酬所有権
Rostislav Raykov
CEO & Director15.2yrsUS$2.54m0.24%
$ 341.5k
Chris Rallis
Independent Director13.1yrsUS$173.18k0.18%
$ 256.5k
Khalid Islam
Independent Chairman of the Board10.4yrsUS$225.23k0.78%
$ 1.1m
Jodi Cook
Independent Director5yrsUS$153.81k0%
$ 0
Marco Brughera
Independent Director8.1yrsUS$166.31k0%
$ 0

10.4yrs

平均在職期間

69yo

平均年齢

経験豊富なボード: FENCの 取締役会 は経験豊富で 経験豊富 です ( 10.3年の平均在任期間)。